SNSE - Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences | Benzinga
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences.
Details of the company's presentations are as follows:
- Keystone Symposia's Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance
Title: VISTA checkpoint targeting by SNS-101, a pH-selective antibody with enhanced safety and pharmacokinetic profiles, alters the tumor microenvironment and overcomes immune checkpoint inhibitor resistance
Presenter: Edward van der Horst, Ph.D., Chief Scientific Officer
Session: Progress in Drugging the TIGIT and VISTA Pathways
Date and time: Tuesday, March 19, 2024, 3 – 4:30 p.m. PT
Material from the presentation will also be presented in a poster at the conference, as detailed:
Poster Number: 3021
Session: Poster Session 3
Date and time: Wednesday, March 20, 2024, at 7:30 p.m. PT - American Association for Cancer Research (AACR) Annual Meeting 2024
Title: Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy
Presentation Type: Poster Presentation
Session Category: Immunology
Session Title: Immune Modulation Employing Agonist or Co-Stimulatory Approaches
Date and Time: Tuesday, April 9, 2024, 1:30 p.m. - 5:00 p.m. PT
Location: Poster Section 3
Abstract Number: 5294
About Sensei Biotherapeutics
Sensei Biotherapeutics (NASDAQ:SNSE) ...